Sansure Biotech Valuation Multiples

Discover Sansure Biotech's revenue and EBITDA valuation multiples and investment history, alongside public comparables like VCANBIO, SonoScape, Tandem Diabetes Care, Weigao Group and more.

Sansure Biotech Overview

About Sansure Biotech

Sansure Biotech Inc is engaged in production and sales of diagnostic reagents and instruments. The company produces Class I medical devices, Class II medical devices, Class III medical devices, general instruments and meters, medical raw materials, medical laboratory equipment and appliances, and medical accessories.


Founded

2008

HQ

China

Employees

N/A

Financials (LTM)

Revenue: $258M
EBITDA: $73M

EV

$913M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sansure Biotech Financials

Sansure Biotech reported last 12-month revenue of $258M and EBITDA of $73M.

In the same LTM period, Sansure Biotech generated $194M in gross profit, $73M in EBITDA, and $34M in net income.


Sansure Biotech P&L

In the most recent fiscal year, Sansure Biotech reported revenue of $243M and EBITDA of $61M.

Sansure Biotech is profitable as of last fiscal year, with gross margin of 76%, EBITDA margin of 25%, and net margin of 12%.

See analyst estimates for Sansure Biotech
LTMLast FY202320242025202620272028
Revenue$258M$243M$149M$216M$243M
Gross Profit$194M$184M$107M$168M$184M
Gross Margin75%76%72%78%76%
EBITDA$73M$61M$78M$64M$61M
EBITDA Margin28%25%53%30%25%
EBIT Margin14%13%5%13%13%
Net Profit$34M$29M$54M$41M$29M
Net Margin13%12%36%19%12%

Financial data powered by Morningstar, Inc.

Sansure Biotech Stock Performance

Sansure Biotech has current market cap of $1.3B, and enterprise value of $913M.

Market Cap Evolution


Sansure Biotech's stock price is $2.28.

Sansure Biotech has an EPS (earnings per share) of $0.05.

See more trading valuation data for Sansure Biotech
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$913M$1.3B-0.8%---$0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sansure Biotech Valuation Multiples

Sansure Biotech trades at 3.5x EV/Revenue multiple, and 12.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Sansure Biotech

Sansure Biotech Financial Valuation Multiples

As of August 6, 2026, Sansure Biotech has market cap of $1.3B and EV of $913M.

Sansure Biotech has a P/E ratio of 39.3x.

LTMLast FY202320242025202620272028
EV/Revenue3.5x3.8x6.1x4.2x3.8x
EV/EBITDA12.6x15.0x11.6x14.3x15.0x
EV/EBIT25.5x29.3x119.4x33.1x29.3x
EV/Gross Profit4.7x5.0x8.6x5.4x5.0x
P/E39.3x44.8x24.5x32.3x44.8x
EV/FCF16.7x(42.9x)(17.7x)(42.0x)(33.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sansure Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sansure Biotech Margins & Growth Rates

Sansure Biotech grew revenue by 11% and EBITDA by 37% in the last fiscal year.

In the most recent fiscal year, Sansure Biotech reported gross margin of 76%, EBITDA margin of 25%, and net margin of 12%.

See estimated margins and future growth rates for Sansure Biotech

Sansure Biotech Margins

Last FY202420252026202720282029
Gross Margin76%78%76%74%
EBITDA Margin25%30%25%31%
EBIT Margin13%13%13%15%
Net Margin12%19%12%14%
FCF Margin(9%)(10%)(11%)39%

Sansure Biotech Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth11%45%13%11%
Gross Profit Growth9%58%10%9%
EBITDA Growth37%(19%)(5%)37%
EBIT Growth28%261%13%28%
Net Profit Growth24%(24%)(28%)24%
FCF Growth(598%)(58%)27%(485%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Sansure Biotech Operational KPIs

Sansure Biotech's Rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sansure Biotech's Rule of X is 59% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Sansure Biotech
LTMLast FY202320242025202620272028
Rule of 4041%42%---
Bessemer Rule of X61%59%---
S&M Expenses to Revenue36%36%13%14%10%
G&A Expenses to Revenue13%13%7%9%13%
R&D Expenses to Revenue13%14%19%19%14%
Opex to Revenue-63%66%65%63%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sansure Biotech Competitors

Sansure Biotech competitors include VCANBIO, SonoScape, Tandem Diabetes Care, Weigao Group, Haier Biomedical, Medartis, Vitrolife, Sinocare, Artivion and Integra Lifesciences.

Most Sansure Biotech public comparables operate across Medical Devices, Diagnostics & Genomics, Life Sciences Tools, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
VCANBIO5.0x-21.5x-
SonoScape3.3x3.1x28.1x23.9x
Tandem Diabetes Care1.5x1.4x(32.7x)101.2x
Weigao Group4.7x4.8x13.5x13.5x
Haier Biomedical3.3x3.2x19.6x18.7x
Medartis4.4x4.0x26.7x22.3x
Vitrolife3.5x3.7x12.3x11.8x
Sinocare2.0x1.9x23.8x16.7x

This data is available for Pro users. Sign up to see all Sansure Biotech competitors and their valuation data.

Start Free Trial

Sansure Biotech VC Funding History

Before going public, Sansure Biotech raised $77M in total equity funding, across 1 round.


Sansure Biotech Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jan-18Strategic investmentHighlight Capital; Lilly Asia Ventures$77M-Sansure Biotech, a molecular diagnostics company based in Changsha, China, raised approximately $77 million (over RMB500 million) in a funding round around early 2018 led by Lilly Asia Ventures and Highlight Capital, with participation from June Capital. The company develops and provides innovative molecular diagnosis and genetic testing kits and tools to diagnostic labs and researchers, including nucleic acid extraction kits, real-time PCR diagnostic and research kits, and fluorescence systems. Sansure claims to be the second-largest company in its market niche in China. Later developments include an IPO raising $294.22M on August 28, 2020. The company has made 4 investments, with the latest in Shengwei Kunteng's Series A on December 23, 2024.

Investments by Sansure Biotech

Sansure Biotech has invested in 4 companies to date.

Latest investment by Sansure Biotech was on August 4th 2026. Sansure Biotech invested in Phil Rivers Technology in their $30M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Sansure Biotech

Phil Rivers Technology
GeneMind Biosciences
SanVectron
Singlera Genomics
Description
Phil Rivers Technology delivers a biotechnology platform combining digital twin modeling with information technology for oncology drug development, headquartered in the United States. Its technology identifies medication targets, matches indications, and predicts therapy responders using multi-omics data integration. The platform supports pharmaceutical research by simulating patient responses and optimizing clinical trial designs. Phil Rivers Technology collaborates with academic institutions and biotech firms on precision medicine applications.
GeneMind Biosciences produces third-generation single-molecule gene sequencing systems, delivering advanced tools for clinicians and researchers through ongoing technological breakthroughs.
SanVectron is a medical device distributor specializing in laboratory analysis instruments and consumables across Europe. The company supplies mass spectrometers, HPLC systems from brands like Agilent and Thermo Fisher, alongside single-use surgical tools for hospitals in Germany and neighboring countries.
Singlera Genomics is a Hangzhou-based firm offering non-invasive tests for cancer detection and prenatal screening. Methylation sequencing platforms like cfMeDIP detect tumor DNA in blood for colorectal and liver cancers. Services extend to pre-implantation genetic diagnosis using IVF clinics in China and US.
HQ CountryChinaChinaChinaUnited States
HQ City
Beijing
Guangzhou
Changshan
San Diego, CA
Deal Date4 Aug 202610 Mar 202523 Dec 20248 Jun 2022
RoundSeries AUndisclosed stageSeries ASeries B
Raised$30M$39M$28M$45M
InvestorsZhangjiang Science & Technology Investment Corporation; Sansure Biotech; CAS StarGuangzhou Kingmed; Voyagers Capital; JinHe Ziben; Rongquan Venture Capital; Qianhe Capital; Sansure Biotech; Shuangye Venture CapitalVoyagers Capital; Rongquan Venture Capital; Sansure BiotechVenture capitalist; FutureX Capital; Sansure Biotech; Junci Investment; Linden Asset; China Galaxy Securities; Best
Valuationundisclosed$573Mundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sansure Biotech investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sansure Biotech

When was Sansure Biotech founded?Sansure Biotech was founded in 2008.
Where is Sansure Biotech headquartered?Sansure Biotech is headquartered in China.
Is Sansure Biotech publicly listed?Yes, Sansure Biotech is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Sansure Biotech?Sansure Biotech trades under 688289 ticker.
When did Sansure Biotech go public?Sansure Biotech went public in 2020.
Who are competitors of Sansure Biotech?Sansure Biotech main competitors include VCANBIO, SonoScape, Tandem Diabetes Care, Weigao Group, Haier Biomedical, Medartis, Vitrolife, Sinocare, Artivion, Integra Lifesciences.
What is the current market cap of Sansure Biotech?Sansure Biotech's current market cap is $1.3B.
What is the current revenue of Sansure Biotech?Sansure Biotech's last 12 months revenue is $258M.
What is the current revenue growth of Sansure Biotech?Sansure Biotech revenue growth (NTM/LTM) is 13%.
What is the current EV/Revenue multiple of Sansure Biotech?Current revenue multiple of Sansure Biotech is 3.5x.
What is the current EBITDA of Sansure Biotech?Sansure Biotech's last 12 months EBITDA is $73M.
What is Sansure Biotech's EBITDA margin?Sansure Biotech's last 12 months EBITDA margin is 28%.
What is the current EV/EBITDA multiple of Sansure Biotech?Current EBITDA multiple of Sansure Biotech is 12.6x.
What is the current FCF of Sansure Biotech?Sansure Biotech's last 12 months FCF is $55M.
What is Sansure Biotech's FCF margin?Sansure Biotech's last 12 months FCF margin is 21%.
What is the current EV/FCF multiple of Sansure Biotech?Current FCF multiple of Sansure Biotech is 16.7x.
How many companies Sansure Biotech has acquired to date?Sansure Biotech hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Sansure Biotech has invested to date?As of August 2026, Sansure Biotech has invested in 4 companies.
What was the last Sansure Biotech investment?On 4th August 2026 Sansure Biotech invested in Phil Rivers Technology, participating in a $30M Series A round, alongside Zhangjiang Science & Technology Investment Corporation and CAS Star.
In what companies Sansure Biotech invested in?Sansure Biotech invested in Singlera Genomics, GeneMind Biosciences, Phil Rivers Technology, and SanVectron.

See public comps similar to Sansure Biotech

Lists including Sansure Biotech

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial